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ARTICLE
Whole-genome landscape of mucosal melanoma
reveals diverse drivers and therapeutic targets
Felicity Newell1,14, Yan Kong2,14, James S. Wilmott3,4,14, Peter A. Johansson1, Peter M. Ferguson 3,4,
Chuanliang Cui2, Zhongwu Li2, Stephen H. Kazakoff1, Hazel Burke4, Tristan J. Dodds3,4, Ann-Marie Patch 1,
Katia Nones1, Varsha Tembe5, Ping Shang4, Louise van der Weyden6, Kim Wong 6, Oliver Holmes1,
Serigne Lo 3,4, Conrad Leonard1, Scott Wood1, Qinying Xu1, Robert V. Rawson3,7, Pamela Mukhopadhyay1,
Reinhard Dummer8, Mitchell P. Levesque8, Göran Jönsson9, Xuan Wang2, Iwei Yeh10, Hong Wu11,
Nancy Joseph12, Boris C. Bastian 10, Georgina V. Long3,4,13, Andrew J. Spillane3,4, Kerwin F. Shannon3,4,
John F. Thompson 3,4,7, Robyn P.M. Saw3,4, David J. Adams6, Lu Si2, John V. Pearson1, Nicholas K. Hayward1,15,
Nicola Waddell1,15, Graham J. Mann3,5,15, Jun Guo2,15 & Richard A. Scolyer 3,4,7,15
Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited due to the
paucity of comprehensive mutation data on this rare tumor type. To better understand the
genomic landscape of mucosal melanoma, here we describe whole genome sequencing
analysis of 67 tumors and validation of driver gene mutations by exome sequencing of 45
tumors. Tumors have a low point mutation burden and high numbers of structural variants,
including recurrent structural rearrangements targeting TERT, CDK4 and MDM2. Significantly
mutated genes are NRAS, BRAF, NF1, KIT, SF3B1, TP53, SPRED1, ATRX, HLA-A and CHD8. SF3B1
mutations occur more commonly in female genital and anorectal melanomas and CTNNB1
mutations implicate a role for WNT signaling defects in the genesis of some mucosal mel-
anomas. TERT aberrations and ATRX mutations are associated with alterations in telomere
length. Mutation profiles of the majority of mucosal melanomas suggest potential suscept-
ibility to CDK4/6 and/or MEK inhibitors.
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Mucosal melanoma arises from melanocytes that reside ina range of internal epithelial tissues of ectodermal ori-gin. The oral cavity, nose and paranasal sinuses, genital
tract, and anorectal region are the commonest primary sites for
mucosal melanoma. In populations where cutaneous melanoma is
common, chiefly those of European background, it accounts for
fewer than 1% of all melanomas, but in other populations
mucosal melanomas can comprise 25% of all melanomas1. Its
causes are unknown, although recent genomic studies have sup-
ported the concept that solar ultraviolet radiation (UVR) is not
the principal carcinogen involved. Studies using exome2–6 or
whole-genome sequencing2,7 have shown that mucosal melano-
mas have a much lower burden of point mutations and a greater
load of structural chromosomal variants compared to cutaneous
melanomas, and that these mutations bear essentially no sig-
natures of UVR or any other known carcinogen. In this they
resemble acral melanomas, those of the volar surfaces of hands,
feet, fingers, and toes, for which etiology is also unknown.
Mucosal melanomas are challenging to treat. Compared to
cutaneous melanoma they are typically detected at a more
advanced stage, lack dominant MAP kinase-activating mutations,
and respond to immunotherapy less frequently8,9. To date, only
limited progress has been made in identifying actionable driver
mutations for this disease. Alterations to SF3B1, KIT, and NF1 are
relatively common compared to cutaneous melanomas7, while
mutations to BRAF and NRAS are less frequent in mucosal
melanomas3,4,10. Similar to some cutaneous melanomas, BRAF
fusions occur in mucosal melanoma, although they are rare.
Tumors carrying such fusions are somewhat sensitive to anti-
MEK targeted therapy, but long-term disease control is rarely
achieved11.
As some of the basic biology of mucosal melanoma remains
unclear, limiting both prevention and treatment, here we conduct
the largest genomic analysis to date of mucosal melanomas (n=
112) from China, Australia, the United States, and Europe. Using
whole-genome sequencing (WGS), we analyze 67 fresh-frozen
tumors and validate the key driver genes in whole-exome
sequence (WES) data. We identify diverse drivers that indicate
the majority of mucosal melanomas are potentially susceptible to
CDK4/6 and/or MEK inhibitors.
Results
Study sample and approach. Sixty-seven patients with fresh-
frozen tumors were included in the WGS analysis and 45 with
FFPE tumors in the validation cohort. Demographic, country of
origin, and clinicopathologic details of the 67 patients and their
tumors that underwent WGS are presented in Supplementary
Data 1. Samples comprised 12 anorectal, 15 female genital, 17
oral, 17 nasal, 2 conjunctival melanomas, and 4 mucosal mela-
nomas of unknown primary site, collected in China (n= 39),
Australia (n= 24), Sweden (n= 3), and Switzerland (n= 1).
Samples from China were predominantly from upper body sites
(31/39) and samples from Australia and Europe were mostly from
lower body sites (20/28). Samples were from primary tumors
(n= 31) as well as recurrent and metastatic sites (n= 26), with 10
of unknown type. Survival and treatment data are included in
Supplementary Data 1; however, due to short follow-up times in
the samples from China (all under 2 years, median of
4.4 months), associations of survival with genomic features were
not formally analyzed.
Samples underwent WGS to an average read depth of 55×
(range 42–100×) in the tumor sample and 31× (range 21–55×) in
the matched normal DNA. Ethnicity of patients was determined
by using principal component analysis to compare the genotypes
of WGS samples with 1000G phase III samples of known
populations (Supplementary Fig. 1). All Chinese samples and one
Australian sample (n= 40) clustered with the East Asian ancestry
super population. Twenty-four samples clustered with samples of
European ancestry and three remaining Australian samples had
an ancestry that was not European or East Asian. Genetic
ancestry was used for subsequent comparisons between samples
in terms of genomic features in this study. Based on genetic
ancestry, the age at diagnosis of mucosal melanoma was younger
in patients of East Asian ancestry, compared with patients of
European ancestry (Mann–Whitney, P= 0.01, mean age 53
vs 63).
The validation cohort derived from FFPE mucosal tumors
from the UK and USA comprised 4 anorectal, 21 female
urogenital, 3 oral, and 17 nasal tumors, and underwent WES to
an average depth of 75× (range 25–106×) in the tumor sample
and 88× (range 48–115×) in the matched normal sample
(Supplementary Data 2).
Point mutation burden and mutational signatures. In keeping
with our previous report for this tumor type7, all mucosal mel-
anomas showed a low single-nucleotide variant (SNV) and
insertion/deletion (indel) mutation burden, with an average of 2.7
mutations per Mb (range 0.54–7.1) (Fig. 1a). Tumors from oral,
conjunctival, and nasal locations had modestly higher rates than
those from the anorectal and urogenital tracts (Mann–Whitney,
P= 0.08). Tumor samples that were primary tumors had a sig-
nificantly lower mutation load than samples from recurrent/
metastatic sites (Mann-Whitney, P= 0.033).
When the flanking nucleotide context of these mutations was
analyzed, seven single base pair substitution mutational signa-
tures were identified (Fig. 1b, Supplementary Fig. 2a). In contrast
to cutaneous melanomas, which typically are dominated
(70–95%, Supplementary Fig. 2b) by UVR-related COSMIC
signature 7 (ref. 7), most mucosal tumors showed no or low
contribution from signature 7. Interestingly, aside from a
conjunctival melanoma, which as would be expected, had a high
UVR signature contribution, five other tumors showed >50%
contribution (Supplementary Fig. 2b), all of which were from
upper mucosal body sites (and of Chinese origin), except one
from an unknown primary site (Fig. 1a, c). There were no
significant differences in the number of SNVs/indels, structural
variants, or percent of the genome affected by copy number
aberrations between samples with >50% UVR signature and <50%
UVR signature.
The contribution of the ubiquitous age-related signature 1 was
more prominent in lower compared with upper body mucosal
sites (Mann–Whitney, P < 0.0001) with no significant difference
in age between patients with upper or lower body site tumors
(Mann–Whitney, P= 0.22) (Fig. 1c). However, lower body site
tumors in this study are predominantly from European patients
and there was a significant difference in the age at diagnosis
between patients of European and Asian ancestry (Mann–
Whitney, mean age 63 vs 53, P= 0.01). Three other signatures
were found to closely resemble previously identified signatures (as
determined by cosine similarity): the ubiquitous signature 5,
signature 17, and a signature similar to signature 3, which we
termed signature 3-like (Supplementary Fig. 2a) and is a
composite of signatures 3, 39, and 40. Signature 3 has been
associated with BRCA1, BRCA2, and/or PALB2 mutations12–14.
However, no pathogenic germline variants or biallelic loss of
somatic mutations in BRCA1, BRCA2, or PALB2 was identified in
the samples with >50% contribution of the signature 3-like
signature. Therefore, in mucosal melanoma this signature may be
due to contributions from signatures 39 and 40, which have no
known etiology. Signature 17, of unknown etiology, was present
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only in samples (n= 6) of Chinese ancestry, and mostly in upper
body mucosal sites.
The final two mutational signatures were recently reported
signatures by PCAWG Pan-Cancer mutational signature analy-
sis15. These signatures are signature 38, which is found almost
exclusively in melanomas and is proposed to be caused by an
indirect effect of UVR, and signature 31, which was dominant in
only one of the mucosal melanomas. Signature 31 (and the closely
related signature 35) has been associated with cisplatinum
treatment16, and the patient with the dominant signature 31 in
their melanoma was subsequently confirmed to have received
several rounds of cisplatinum chemotherapy prior to their biopsy
being removed. Consistent with previous observations, signature
31 displayed strand bias in the opposite direction to the UVR-
related signature 7 and had a high proportion of CT > AC
dinucleotide substitutions. In contrast, signature 7 exhibited the
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Fig. 1 Mutational signatures. a Mutation burden (top) and proportion of mutational signature (second from top) per sample. The tumor purity, country of
origin, site, and region for each sample is shown beneath the plot. b Seven mutational signatures were identified in the WGS cohort. For each signature, the
mutational type probability for each substitution in a trinucleotide context is shown (total 96 contexts). UVR ultraviolet radiation. c Proportion of each
signature in tumors from the upper: nasal, oral eye and lower: anorectal and genitourinary body sites. Source data for Fig. 1c are provided as a Source
Data file
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typical CC > TT dinucleotide substitutions that are due to UVR
(Supplementary Fig. 2c, d).
Burden and patterns of structural variants. Tumors had a mean
of 260 structural variants (SVs) per tumor (range 21–1300).
When classified as rearrangement signatures according to SV
spatial distribution and fragment size composition17, five rear-
rangement signatures were identified (Fig. 2a) and were com-
pared with previously described rearrangement signatures17 by
cosine similarity. All signatures had a similarity of >0.8 and were
identified as RS4 (similarity: 0.99), RS6 (0.97), RS2 (0.98), RS1
(0.85), and RS5 (0.86). RS4 and RS6 are characterized by clustered
SV breakpoints, with RS4 having a high number of inter-
chromosomal translocations and RS6 having clustered inversions,
duplications, and deletions. Unsupervised hierarchical clustering
based on the proportions of rearrangement signatures identified
two groups of tumors (Fig. 2b). Twenty-eight tumors were
characterized by high overall SV counts, clustered breakpoints, a
dominance of signatures RS4 and RS6, and a high number of
kataegis loci (localized regions of substitution hypermutation)
(Group 1). The remaining 39 tumors contained a lower number
of SV counts, with dominant unclustered SV signatures RS1, RS2,
and RS5 and low numbers of kataegis loci (Group 2) (Fig. 2a).
The relative proportion of Group 1 and Group 2 tumors did not
differ between upper and lower body location (Fisher’s exact, P=
0.45), or by sample genetic ancestry (Fisher’s exact, P= 0.24).
Complex events often targeted chromosomes 5, 11, and 12 and
were primarily present in samples in Group 1 (Fig. 2b). A review of
chromosomes showing evidence of clustered breakpoints revealed
that the localized events had some features of genomic
catastrophes. Although there were some tumors that showed
patterns similar to chromothripsis (clustered breakpoints, oscilla-
tion of copy number, and retention of heterozygosity) and
breakage-fusion-bridge (BFB) (loss of telomeric regions and a
high number of inversions), most events were too complex to
confidently assign to one particular type of mutational mechanism.
Other complex focal events involved amplified loci linked together
by high numbers of translocations. Focal regions on chromosomes
5p (Supplementary Fig. 3a), 11q (Supplementary Fig. 3b), and 12q
(Supplementary Fig. 3c) were particularly targeted, and had a high
density of SV breakpoints, and in about 20% of the tumors the
regions also contained highly amplified loci. These amplified loci
encompassed known melanoma drivers TERT (chr5), CCND1
(chr11), MDM2 (chr12), and CDK4 (chr12)7,18 (Supplementary
Fig. 3d–f), as well as other genes reported to be amplified and/or
overexpressed in melanoma19,20 including SKP2 (chr5) and GAB2
(chr11). Examples of targeted regions in specific samples are shown
in Supplementary Fig. 4a–c. Of note, eight samples showed
multiple (>5 per sample) translocation events between 5p and 12q
(Supplementary Fig. 4d), suggesting that these recurrent events are
positively selected. Most of the samples with chromosome 5p–12q
translocations were oral mucosal melanomas (7 oral, 1 anorectal),
of East Asian ancestry (7 East Asian, 1 European), had
amplifications of CDK4 or MDM2 (7/8) on chromosome 12 and
TERT or SKP2 (4/8) on chromosome 5 and were, on average,
younger at tumor diagnosis when compared with the overall
cohort (P= 0.006, mean age 42 vs 58). When analyzing oral
mucosal samples alone, samples with chr5p–12q translocations
also had a lower age at diagnosis (Mann–Whitney, P= 0.008,
mean age 39 vs 58 any ancestry, P= 0.01 samples of East Asian
ancestry only), but no difference by gender.
Focal regions of structural rearrangements on chromosomes
such as 5p, 12p, and 11p also co-localized with regions of
localized hypermutation, termed kataegis21. The trinucleotide
context of SNVs that fell within kataegis loci displayed
characteristics of mutational signatures 2 and 13 which are
associated with APOBEC deamination (Supplementary Fig. 3g).
APOBEC signatures were not identified in the mutational
signature analysis for the cohort overall (Fig. 1), but this is likely
due to the low number of SNVs contained within kataegis loci
compared with the overall number of SNVs (0.6%).
Significantly mutated genes. Supplementary Data 3 lists all
coding SNVs/indels in the mucosal melanomas subjected to
WGS. To identify significantly mutated genes (SMGs), we used a
consensus approach involving five tools: the Oncodrive suite of
tools (OncodriveFM, OncodriveFM, and OncodriveFML),
MuSiC2, 20/20+, dNdScv, and MutSigCV. A total of 10 genes
were identified as significantly mutated: NRAS (12/67), BRAF (11/
67), NF1 (11/67), KIT (10/67), SF3B1 (8/67), TP53 (6/67),
SPRED1 (5/67), ATRX (4/67), HLA-A (4/67), and CHD8 (3/67)
(Fig. 3a, Supplementary Fig. 5, Supplementary Data 4). The BRAF
mutations were diverse (Fig. 3b), but all mutations were in the
protein tyrosine kinase domain and most targeted the 594–600
amino acids hotspot region. NRAS mutations were targeted to
hotspots on codon 61, which is the dominant hotspot in cuta-
neous melanoma, and codon 12, a hotspot less commonly
mutated in cutaneous melanoma7,18,22,23 (Fig. 3b). The MAPK
pathway-activating mutations were almost completely mutually
exclusive, as previously reported7,18,23. NRAS mutations were
mostly found in samples from recurrent/metastatic sites (two
primary, eight recurrent/metastatic, two unknown, Fisher’s exact,
P= 0.032). Interestingly, there was little overlap between tumors
with MAPK pathway mutations and SF3B1-mutated tumors,
suggesting that the latter mutations may result in MAPK acti-
vation. All SF3B1 mutations targeted the 625 codon hotspot
(Fig. 3b), and all but one of the SF3B1-mutated tumors originated
from anorectal or female genital sites. SF3B1 mutations were also
mostly in mucosal melanomas of European ancestry (7/8) and all
were from primary tumor samples. BRAF mutations were rare in
the nasal cavity, with no codon 600 mutations and only one G-
loop mutation identified (G469A). The six tumors with >50% UV
signature had no statistically significant difference in driver genes
mutations, but lacked mutations in TP53, SPRED1, SF3B1. There
were no other relationships evident between SMGs and primary
melanoma anatomic site, primary compared with metastatic/
recurrent site or patient ancestry.
The SMGs were assessed in a validation FFPE tumor set that
underwent WES analysis (Fig. 3c, Supplementary Fig. 5). The
HLA-A and CHD8 genes were not mutated in this set and are
therefore potential false-positive SMGs, but other genes showed
mutations at a similar frequency to the discovery set, with two
exceptions: BRAF and SPRED1, each mutated in only 1/45 WES
tumors. Once again, SF3B1 mutations were also predominant (5/6)
in tumors from anogenital regions.
Since SMG algorithms do not consider promoter mutations, we
discuss TERT promoter mutations below in the context of other
telomere maintenance genes and mutational mechanisms.
Other cancer driver gene mutations. We looked for somatic
mutations in other known driver genes, either previously reported
for melanoma or in other cancer types. Four WGS samples car-
ried somatic mutations of CTNNB1 (Supplementary Data 3). Two
samples were from Australia (an anorectal melanoma with p.
L31_I35del and a mucosal melanoma arising in the lacrimal sac
with p.S33C) and two were from China (a nasal melanoma with
p.T41A and an oral melanoma carrying both p.P44A and p.S45P
mutations on the same haplotype). Two samples in the WES
validation cohort also had CTNNB1 mutations. All of these
mutations occurred at documented hotspots in various cancer
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Fig. 2 Structural variant complexity. a Five rearrangement signatures (RS) were identified. Rearrangements were classified into 32 categories based on the
rearrangement size, type (Del= deletion, Dup= duplication, Inv= inversion, T= translocation) and whether breakpoints are clustered (left) or non-
clustered (right). b Two groups of tumors following clustering with ConsensusClusterPlus. Plots from top to bottom are: number and type of SVs;
proportion of each rearrangement signature (light blue= lower, dark blue= higher); evidence of localized complexity per chromosome, per sample (light
= lower, dark= higher); number of kataegis loci per chromosome, per sample; total number of kataegis loci per sample; tumor ploidy; tumor purity; sample
origin, sample ancestry, tumor body site, and body region
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types24. Additionally, in single WGS samples, we noted hotspot
activating mutations in the oncogenes MAP2K1, GNAQ, and
KRAS as well as unambiguous loss-of-function (LoF) mutations
in the tumor suppressor genes CDKN2A (nonsense), BAP1 (fra-
meshift), MEN1 (nonsense), and NF2 (frameshift).
Recurrent copy number and structural events. We then iden-
tified genes with significant copy number variations (CNVs)
identified by GISTIC, and genes recurrently affected by SV
breakpoints that are COSMIC cancer census genes, genes iden-
tified by SMG analysis in this study, or previously identified
melanoma driver genes (Fig. 4, Supplementary Fig. 6). This
analysis revealed strong similarities with melanomas of cutaneous
(including acral) sites, with frequent targeting of TERT, CCND1,
KIT, MITF, CCND1, MDM2, CDK4, and NOTCH2 by amplifi-
cation (Fig. 4c, d), and copy loss of NF1, PTEN, CDKN2A, ATM,
and ARID1B (Fig. 4c, e). CDK4 and MDM2 were frequently co-
amplified on chromosome 12, often along with TERT, on chro-
mosome 5, via linking translocations. We observed homozygous
deletion of SPRED1 in two tumors (Fig. 4e). The only gene where
CNV abberations was associated with ancestry was NOTCH2
amplifications, with 4/6 aberrations being in European tumors.
SV breakpoints were also observed in SPRED1 and breakpoints
commonly occurred in melanoma genes CDKN2A, NF1, and
PTEN. The SV resulted in 391 predicted fusion events affecting
657 genes (Supplementary Data 5); however, none involved
gene pairs that occurred in more than one sample. Two genes
(FAM19A2 and TENM4) were involved in four fusion pairs,
and four genes (SHANK2, KHDRBS2, PTPRR, and RGL1) were
involved in three fusion pairs. Only FAM19A2 has the same
protein region retained in two samples, but these also
have multiple predicted LoF SVs in the gene. Given FAM19A2
is in the same chromosomal region as MDM2/CDK4, these may
be passenger events that are not functionally relevant. Aside from
a GRM3 fusion in a mucosal melanoma that we previously
reported7, we observed single gene fusion events affecting BRAF,
PAK1, and DGKB, consistent with our observations in cutaneous
melanoma7,25.
TERT, ATRX, and telomere length. When relative telomere
length (TL) in tumor was compared with TL in matched normal,
56% of mucosal melanomas exhibited TL shortening. We related
tumor TL to primary tumor site and mutations in key genes
affecting telomere biology26 (Fig. 5). Putatively activating TERT
mutations were observed in one-third of tumors (6/67 promoter
SNV, 15/67 by high level copy number gain including 1/67 with
both promoter SNV and copy number high level gain) and were
generally associated with shorter TL (Mann–Whitney, P=
0.0079) (Fig. 5, Supplementary Fig. 7a). In contrast, ATRX
mutations were less frequent (4/67 inactivating SNVs and 3/67
SVs; one with both SNV and SV) and were associated with
increased TL (P= 0.0025; Supplementary Fig. 7b). There was a
trend for TP53 SNV/indel mutated samples to display telomere
elongation (P= 0.12; Supplementary Fig. 7c) and when copy
number loss (copy number 1) and copy neutral LOH were also
considered there was a modest association with telomere elon-
gation (Mann–Whitney, P= 0.0495; Supplementary Fig. 7d), as
previously reported26. There were no associations with other
previously reported TL-associated genes DAXX, RB1, VHL,
PBRM1, or NRAS (Supplementary Fig. 7e). Activating TERT
mutations and loss of function ATRX mutations were mutually
exclusive, as has also been observed in gliomas27. For 4/6 ATRX-
mutated samples, TP53 SNV mutations also occurred. In addi-
tion, in the WES cohort, all three LoF ATRX mutations also co-
occurred with TP53 mutations. When TL was assessed against
putative mucosal cancer drivers identified in this study, a strong
correlation with KIT activating mutations and telomere short-
ening was observed (P= 0.0018, Supplementary Fig 7f). Lower
body site (P= 0.0022) (Supplementary Fig. 7g, h) and tumors
from patients of European ancestry (Mann–Whitney, P= 0.013)
were also associated with reduced TL.
Candidate driver events summary and clinical implications.
Mucosal melanomas carried an average of four (range 0–15)
established and putative driver gene aberrations (of all types)
(Fig. 6a, Supplementary Data 6). Overall, all but one tumor (66/
67) had at least one well-established driver gene mutation
(Fig. 6a), i.e. MAPK pathway (NF1, NRAS, KIT, BRAF), SF3B1,
TP53 and MDM2, SPRED1, TERT and ATRX, CDK4 and CCND1
(Fig. 6b). When comparing the profile of mutations of mucosal
melanomas from East Asian and European ancestry, there were
no differences in the presence of driver mutations in any parti-
cular genes, with the exception of SF3B1 which was predominant
in patients of European ancestry (Fisher’s exact, P= 0.011).
When comparing any aberration with respect to primary and
recurrent/metastatic sample types, SF3B1 (Fisher’s exact, P=
0.0057) and SPRED1 (Fisher’s exact, P= 0.02) mutations were
mostly present in primary samples and NRAS aberrations were
predominantly in recurrent/metastatic tumors.
Actionable mutations were identified using the Cancer
Genome Interpreter website to annotate mutations in the sample
that are predicted to confer response (Fig. 6c) or resistance to a
targeted agent (Fig. 6d). The inhibitors with the highest levels of
evidence included three patients with BRAF V600E where FDA
guidelines indicate use of BRAF and/or MEK inhibitors and seven
samples with KIT mutations. Notably, a large proportion of the
cohort (47/67, 70%) harbored mutations potentially responsive to
CDK4/6 inhibitors, although the evidence for such treatments is
in the lower confidence categories of case reports and early trials.
The driver mutations identified as responsive to CDK4/6
inhibitors include CDK4 and CCND1 amplifications, as well as
CDKN2A deletions. In addition, although not identified as a
significantly mutated driver, a number of samples also had CDK6
amplifications (9/67, 13%) that indicates potential sensitivity to
CDK4/6 inhibitors. The analysis also identified a MITF
amplification, NF1 mutation, and a mutation in MAP2K1
(encoding MEK1) that may confer resistance to MEK/MAPK
inhibitors.
Discussion
This is the largest analysis of mucosal melanoma performed to
date that uses high-coverage WGS to compare melanomas from
different body sites and from European and Asian populations.
We show different mutational signatures (based on UVR-related
and endogenous mutagenic processes) occur in mucosal mela-
nomas arising in facial sites compared to those arising in lower
body sites and signatures 7 and 17 occur more often in patients of
East Asian ancestry. Additionally, the frequency of specific driver
mutations varies with primary melanoma site. For example,
SF3B1 hotspot mutations are common in anorectal and vulvo-
vaginal melanomas but are rare in mucosal melanomas from
other sites3,28 and BRAF mutations are less common in the nasal
cavity. Conversely, while there are two distinct groups of tumors
based on the number and distribution of chromosomal SVs, these
do not relate to primary melanoma site or genetic ancestry.
Together, our results demonstrate that mucosal melanomas show
considerable heterogeneity based on the underlying mutagenic
processes and body site-specific driver mutations and that genetic
ancestry or geographic location may also be factors associated
with this.
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The large number of samples from a range of different primary
tumor sites enabled us to perform the first detailed character-
ization of the mutagenic processes that underlie mucosal mela-
noma. Interestingly, in contrast to prior reports, mutations
resulting from UVR exposure were identified in some melanomas
from facial mucosal sites while confirmed to be absent from lower
body mucosal sites. The presence of a UVR-related signature in a
conjunctival melanoma was expected, given the direct exposure of
this site to solar UVR; however, our data show that some mucosal
melanomas in the nasal cavity, nasal sinuses, and oral cavity have
also arisen under a degree of UVR exposure. Nevertheless, when
compared with cutaneous melanomas7, the UVR-related muta-
tion load of sinonasal and oral mucosal melanomas is low.
However, the evidence of UVR-related mutagenesis in mucosal
melanomas of the facial area implicates reflected or attenuated
UVR exposure as a carcinogen even in these relatively sun-
shielded sites. The fact that UVR signatures occur predominantly
in samples of East Asian ancestry may be because mostly upper
body site tumors in this study were from Chinese patients, or may
reflect other geographic factors. Likewise, that signature 17
occurred only in patients of East Asian ancestry also indicates
geographically specific environmental or genetic factors may play
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a role in the development of mucosal melanomas. A larger cohort
of samples from each ethnicity would be required to fully eluci-
date these factors.
Nevertheless, most of the mutation burden in mucosal mela-
noma cannot be assigned to known carcinogens. The dominant,
non-UVR-related mutagenic processes included the clock-like
(age-related) mutational processes of signature 1 (spontaneous
deamination of 5-methylcytosine), an endogenous process that is
active in the vast majority of cancers15. Significantly higher
proportions of signature 1-related mutations were present in the
mucosal melanomas of lower than upper body sites. The process
of spontaneous deamination of 5-methylcytosine has been shown
to correlate with mitotic divisions and age of cancer diagnosis15.
While there was no significant difference in age of diagnosis
between the patients with upper and lower body mucosal mela-
nomas, patients of East Asian ancestry, which made up the
greater proportion of upper body site tumors were, on average,
older than patients of East Asian ancestry. Therefore, further
work is required to establish if the presence of more signature 1 in
the lower body site tumors reflects real site-specific biology or is a
result of the ethnicity of the patients whose tumors samples were
examined in our study.
Our multi-tool analysis of SMGs identified SPRED1 as a driver
in mucosal melanoma, which was mutated in tumors from a
variety of anatomical sites. SPRED1 is a tumor suppressor that
acts by transporting NF1 to the plasma membrane where it
inhibits RAS-GTP signaling. Recently, Ablain et al.29 reported
SPRED1 loss as a driver of mucosal melanoma. Loss of SPRED1
function results in increased MAPK pathway signaling30. How-
ever, while NF1 and SPRED1 mutations typically co-occur in
cutaneous melanoma7,31, in our study of mucosal melanomas,
most SPRED1 aberrations identified in WGS samples (11/13)
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occurred in NF1 wild-type samples, with only two SVs in SPRED1
co-occurring with NF1 mutations.
As previously reported7,10,31, we found a substantial propor-
tion of mucosal melanomas had aberrations of the MAPK
pathway, including frequent mutations in NRAS, BRAF, NF1, and
KIT. Mutations were also identified in several other known cancer
driver genes, including CTNNB1, implicating the previously
unappreciated role of WNT signaling in the genesis of mucosal
melanomas. Since activation of the Wnt/β-catenin pathway has
also been demonstrated to cause T cell exclusion32, CTNNB1
mutations may also contribute to the relatively poorer responses
to immunotherapy observed in some advanced stage mucosal
melanoma patients33,34 Hotspot mutations were also identified in
the oncogenes MAP2K1 and KRAS, which together with a BRAF
fusion, further highlight the reliance on MAPK pathway activa-
tion in this tumor type.
Our study provides important insights into the complexity and
diversity of the SV load in mucosal melanomas. Many of the SV
events targeted well-known melanoma driver genes (CDKN2A,
NF1, PTEN, and TERT), exemplifying their role in mucosal
melanoma pathogenesis. We found that there were two distinct
subgroups of mucosal melanoma primarily distinguished by their
degree of localized complex chromosomal rearrangement. How-
ever, these clusters did not co-segregate with upper and lower
primary body sites or genetic ancestry suggesting they arise via
alternate common pathways of genome instability some time after
initiation. Regions of localized complexity could be the result of
genomic catastrophes such as chromothripsis. We identified
tumors that showed patterns similar to chromothripsis, as well as
BFB. In addition, we identified a number of tumors with regions
of amplified loci on multiple chromosomes linked by high
numbers of translocations. We have previously observed similar
patterns in ovarian cancer13, and these patterns are characteristic
of double minute chromosomes35,36 or neochromosomes37. A
number of mucosal melanomas in our cohort showed a pattern of
translocations involving 12p amplifications which is similar to
that of neochromosomes in liposarcomas37.
Localized structural rearrangement events targeted a number of
regions, including 5p, 11p, and 12p, with a common consequence
of these complex events being amplification of oncogenes such as
TERT, MDM2, CCND1, CDK4. These regions have also recently
been identified as significantly recurrent breakpoint regions (SRB)
with gene amplifications, and result from positive selection rather
than by genome fragility38. Therefore, amplification of oncogenes
or other cancer genes conferring a growth advantage may be an
important mechanism driving mucosal melanoma.
All but one of the eight tumors in this study with translocations
between 5p and 12p, usually resulting in amplifications of
MDM2/CDK4 and TERT, were oral mucosal melanomas and of
East Asian ancestry. Interestingly, oral mucosal melanomas car-
rying such translocations occurred at significantly younger age
than those without translocations. This finding suggests mole-
cular diversity in predominant driver genes between mucosal
melanomas from different body sites. This notion is supported by
Lyu et al.4, who recently reported amplifications of 12q14 and
5p15 in ~50% of oral mucosal melanomas, and 6/19 tumors had
amplification of both regions.
One potential consequence of genomic instability in mucosal
melanomas is an effect on telomere maintenance and length. A
key event in cellular immortality is the presence of a telomere
maintenance mechanism to escape cellular crisis, potentially
occurring through activation of telomerase (TERT) or through
alternative lengthening of telomeres (ALT), resulting from
ATRX inactivation. We identified mutually exclusive loss of
function ATRX mutations and putatively activating TERT
promoter mutations and amplifications, suggesting that both
maintenance mechanisms are important in distinct subsets of
mucosal melanoma. The association of KIT with TL in this
cohort has not previously been reported, and further work is
required to identify the mechanism behind this association.
The finding of SPRED1 as a driver increases the proportion of
mucosal melanoma samples with a known driver event in the
MAPK pathway (NF1, NRAS, BRAF, SF3B1, TP53, KIT, and
SPRED1) to 92% of the studied patients. MEK/MAPK inhibition
may thus be suitable for a large proportion of mucosal melanoma
patients and warrants evaluation in clinical trials. Driver events
affecting CDK4 in a large proportion of our cases points to the
potential therapeutic option of using CDK4 inhibitors to treat this
tumor type. Indeed, Zhou et al.39 have very recently shown that
such inhibitors are effective in treating patient derived xenografts
of mucosal melanomas carrying CDK4 aberrations, thus pro-
viding experimental support for this notion. Immunotherapies
are standard of care for metastatic cutaneous melanoma patients;
however, mucosal melanoma patients treated with PD-1 anti-
bodies respond half as often as cutaneous melanoma patients8. It
is likely that the low mutation burden in mucosal melanoma is an
important factor in limiting responses to immunotherapies in
mucosal melanoma patients. Our data also suggest that activation
of the β-catenin pathway (through mutations in CTNNB1) may
be a contributing factor32. Improved understanding of the factors
regulating immunogenicity in mucosal melanomas is needed to
improve outcomes for mucosal melanoma patients, along with
comprehensive molecular analysis of both point and structural
mutations to reveal all therapeutic opportunities in this difficult
and diverse class of tumors.
Methods
Human melanoma samples. All fresh frozen and FFPE samples were obtained in a
method that was compliant with the relevant ethical regulations for work with
human participants. The fresh-frozen tissue and matching blood samples (n= 67)
analyzed in the current study were obtained from the biospecimen bank of Mel-
anoma Institute Australia (MIA) (n= 24), Peking University Cancer Hospital &
Institute, Beijing, China (n= 39), the Department of Surgery, Skåne University
Hospital, Sweden (n= 3), and the Biobank of the University Research Priority
Program in translational cancer research (URPP) at the University of Zurich
Hospital, Switzerland (n= 1). All tissues and bloods form part of prospective
collections of fresh-frozen samples accrued with written informed patient consent.
The study was approved by the Sydney Local Health District RPAH zone ethics
committee (Protocol No. X15-0454—previously X11-0289 and HREC/11/RPAH/
444; Protocol No X17-0312—previously X11-0023 and HREC/11/RPAH/32; and
Protocol No X15-0311—previously X10-0300 and HREC/10/RPAH/530) and the
relevant cases were approved by the institutional ethics committees of Peking
University Cancer Hospital & Institute (Beijing Cancer Hospital), Skåne University
Hospital and University of Zurich. Fresh surgical specimens were macro-dissected
and tumor tissues were procured (with as little contaminating normal tissue as
possible) and snap frozen in liquid nitrogen within 1 h of surgery. All samples were
pathologically assessed prior to inclusion into the study, with samples requiring
greater than 80% tumor content and less than 30% necrosis to be included. All
samples were independently reviewed by expert melanoma pathologists R.A.S., P.
M.F. and T.J.D. to confirm the presence of melanoma and fulfillment of the above
criteria as previously described40. All cases were reviewed centrally by the study
pathologists (R.A.S., P.M.F., and Z.L.) to confirm the origin of each tumor from wet
mucosa, rather than the adjacent oral, nasal, anal, or genital skin. Samples requiring
tumor enrichment underwent macrodissection or frozen tissue coring (Cryoxtract,
Woburn, MA, USA) using a marked H&E slide as a reference. Mucosal melanomas
were defined as occurring in the mucosal membranes lining oral, respiratory,
gastrointestinal, and urogenital tracts. The H&E slides of the primary melanomas
were reviewed in all cases and any tumor that had arisen in the junction of mucosal
and cutaneous skin was excluded.
A validation set of human mucosal melanoma cases (n= 45) (defined as
occurring in the mucosal membranes lining oral, respiratory, gastrointestinal, and
urogenital tracts) were obtained as FFPE tissue from three clinical centers:
University of Michigan, University of Edinburgh and University of California, San
Francisco as described by Wong et al.41. All FFPE exome cases were ethically
approved by local Institutional Review Boards at the University of Michigan,
University of Edinburgh and University of California, San Francisco and by the
Sanger Institute’s human materials and data management committee. All samples
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were reviewed by specialist dermatopathologists prior to inclusion into the study.
Cores were taken from samples using a marked H&E slide as a reference.
DNA extractions. Fresh-frozen tumor DNA was extracted using DNeasy Blood
and Tissue Kits (69506, Qiagen Ltd), according to the manufacturer’s instructions.
Blood DNA was extracted from whole blood using Flexigene DNA Kits (51206,
Qiagen Ltd). All samples were quantified using a NanoDrop (ND1000; Thermo-
scientific) and Qubit® dsDNA HS Assay (Q32851; Life Technologies) and DNA
size and quality were tested using gel electrophoresis. Samples with a concentration
of less than 50 ng/µl, or absence of a high molecular weight band in electrophoresis
gels, were excluded from further analyses.
DNA from tumor samples obtained as FFPE tissue cores was extracted with
QIAamp FFPE Tissue kits (Qiagen), according to the manufacturer’s instructions
and quantified using the Qubit® dsDNA HS Assay (Q32851; Life Technologies)41.
WGS, processing, and quality control. Sixty-seven patients underwent whole-
genome paired-end sequencing on a HiSeq2000 or HiSeq X Ten (Illumina, San
Diego, CA, USA) at The Kinghorn Cancer Centre, Garvan Institute of Medical
Research (Sydney, Australia), Macrogen (Geumcheon-gu, Seoul, South Korea), or
Novogene Bioinformatics Technology Co. Ltd, China. Library construction was
performed using TruSeq DNA Sample Preparation kits (Illumina) as per the
manufacturer’s instructions. All downstream processing, including sequence
alignment and variant calling, was carried out at QIMR Berghofer (Brisbane,
Australia) using the same analysis pipeline for all whole-genome samples. Sequence
data were adapter trimmed using Cutadapt (ref. 42; version 1.9) and aligned to the
GRCh37 assembly using BWA-MEM (version 0.7.12) and SAMtools (version 1.1).
Duplicate reads were marked with Picard MarkDuplicates (https://broadinstitute.
github.io/picard (version 1.129); http://picard.sourceforge.net). Assessment of the
sequencing and alignment quality of the sample was carried out using qProfiler
(version 1) and estimation of coverage using qCoverage (version 0.7pre; http://
sourceforge.net/projects/adamajava). All tumors had a minimum tumor purity of
15%. Tumor purity was assessed using ascatNGS. Where ascatNGS was unreliable
(following manual review), mean variant allele frequency was used (Supplementary
Data 1).
Whole-exome sequencing, processing, and quality control. The 45 FFPE-
derived tumor samples that formed the validation cohort underwent whole-exome
sequencing at the Wellcome Trust Sanger Institute (Hinxton, United Kingdom)41.
Sequencing libraries were generated using Agilent SureSelect All Exon V5 kits and
sequenced on the HiSeq2500 platform (Illumina, San Diego, CA, USA) to generate
75 bp reads. Sequence data were aligned to the human genome assembly GRCh38
using BWA-MEM (version 0.7.12) and Biobambam (version 2.0.18) was used to
mark PCR duplicates. BAMs were merged to sample level using SAMtools43. To
ensure that tumor and matched normal samples had the best reciprocal match,
SAMtools mpileup, followed by BCFtools “gtcheck” was run to detect potential
sample swaps and contamination. To assess sequencing and alignment quality,
the SAMtools “stats” utility was used to determine the coverage and PCR
duplicate rate in bait regions plus 100 bp flank on either side. Quality filtered
BAM files were generated for downstream analysis by removing PCR duplicates,
reads that failed Illumina chastity filtering supplementary and secondary read
alignments. In addition, reads were removed where two reads had the same start
position and one read had a mapping quality of zero, and mapped randomly to
a repetitive site, an artifact frequently observed in libraries from FFPE samples.
Assessment of sample swaps and contamination using BCFtools and coverage
metrics was performed again on the quality filtered BAM files.
Whole-genome somatic SNV/indel analysis. Somatic SNV and indels were
detected using an established pipeline7 where a dual calling strategy was used to
detect SNV, with the consensus of two different tools being used for downstream
analysis: qSNP (version 2.0)44 and GATK HaplotypeCaller (version 3.3-0)45.
Detection of indels (1–50 bp) was carried out using GATK. Variant annotation for
gene consequence was performed using SnpEff.
Whole-exome somatic SNV/indel analysis. Somatic SNV were called using
MuTect (v1.1.7)46. MuTect was run with some non-default parameters to deal
with contamination of normal samples with tumor DNA and with quality issues
seen in FFPE samples. Parameters used included: allowing the normal sample to
have <5% of reads with an alternate allele and <4 reads total with the alternate
allele; allowing for some clustering of alternate alleles at a consistent distance
from the start/end of the read by decreasing the requirement for exclusion based
on the fraction of read that is clipped from 0.3 to 0.25; and increasing the
minimum base quality score required in order for a base to be considered. The
base quality score threshold was changed because an artifact (from either PCR or
sequencing) was identified where both low-quality reference bases and mis-
matched bases were consistently present downstream of polynucleotide runs.
MuTect variants were then filtered using tiered BCFtools filtering based on read
depth and variant allele fraction (VAF). SNVs were excluded if they had either: a
depth of less than 10; VAF < 0.20 with depth < 20; VAF < 0.05; VAF > 0.15 and
number of supporting reads <5; VAF < 0.30 and normal contained 3 or more alt
reads; or normal had 2 (or more) alt reads and the tumor VAF was <0.20.
Additional filters were applied to MuTect variants, including removing variants
that are common (>0.01) in gnomAD47 and using SAMtools mpileup to check for
alternate alleles in unrelated normal samples. Variants for which there were three
or more alternate alleles in at least two unrelated normal samples were identified
as falsely somatic and excluded.
As MuTect does not identify multi-nucleotide variants (MNVs), MAC
v1.2 software (Multi-nucleotide Variation Annotation Corrector; https://github.
com/hubentu/MAC) was applied to the variants identified by MuTect. MAC
takes a list of SNVs, checks adjacent and nearby SNVs, and phases them. In-
house scripts were used to take output from MAC, rerun variant effect
prediction on MNVs, and fix VCF entries. Somatic indels were called using
Strelka (v1.0.15)48. Indels were filtered to remove variants that were common
(>0.01) in gnomAD. Mutation consequences for SNVs and Indels were predicted
using Ensembl Variant Effect Predictor (VEP)49 and gene models from Ensembl
release v89.
Determination of sample genetic ancestry. To determine genetic ancestry,
mucosal sample genotypes were compared with the genotypes of populations
examined in the 1000 genomes (1000G) project50. Phase III 1000 genomes
genotypes in plink format were downloaded from the Plink2.0 website (https://
www.cog-genomics.org/plink/2.0/resources#1kg_phase3). For the 67 mucosal
WGS samples, pileups were performed at 1000G SNP positions and a VCF file
generated. A genotype was assigned using the following criteria: (i) homozygous
reference genotype (0/0) if the variant allele fraction (VAF) was ≤0.2; (ii) het-
erozygous (0/1) if the VAF was >0.2 and <0.8; (iii) homozygous (1/1) for the alt
allele if the VAF was ≥0.8. Positions for which the coverage was less than 10 for
any sample were excluded. The VCF file was converted to a plink file and an
ancestry check was performed as per the method outlined in the plinkQC R
package “Ancestry check” vignette. All subsequent analysis was performed using
plink version 1.90b6.8. Genotypes of mucosal samples were pruned for variants
in linkage disequilibrium with an r2 greater than 0.2 in a 50 kb window and
ranges with known high-LD were also removed. The genotypes of 2504 reference
(ie 1000G) samples and 67 mucosal samples were merged after correcting for
chromosome or position mismatches and updating allele flips. Variants with a
missing rate of greater than 0.1 or minor allele frequency of less than 0.05 were
removed. Principal component analysis was performed using 39,156 variants
and principal components 1 and 2 were then plotted using a plotting function in
plinkQC (Supplementary Fig. 1). Samples that did not cluster with European or
East Asian (i.e. Chinese populations) were assigned as Other.
Mutational signatures. The non-negative matrix factorization (NMF) method
described by Alexandrov et al.12 was used to detect mutational signatures in WGS
samples. To determine the contribution of each signature to a sample, we used the
quadratic programming approach available in the R package, SignatureEstima-
tion51 to assign the mutations in each sample to the signatures identified by NMF.
To prevent over-fitting, signatures that contributed less than 10% for a sample were
removed and mutations were reassigned to the signatures that remained. Signatures
that were obtained were compared with the profiles of signatures (SBS1–SBS60)
found in the recent analysis of more than 4000 whole cancer genomes by the Pan
Cancer Analysis of Whole-Genomes network (PCAWG)15. The presence of tran-
scriptional strand bias in signatures was assessed using the R package ‘Mutatio-
nalPatterns’52. Mutational signatures were not analyzed in the FFPE validation
cohort due to low mutation number.
SMG analysis. We used a consensus approach and multiple tools for discovery
of SMGs affected by SNVs/indels. These tools comprise the Oncodrive suite of
tools53,54, MuSiC2 (ref. 55), 20/20+56, dNdScv57, and MutSigCV. Unless
otherwise specified all tools were run using default parameters. The Oncodrive
suite consisted of three methods: OncodriveFM, OncodriveClust, and Onco-
DriveFML. OncodriveFML was executed using CADD v1.0 through the web
interface at: http://bbglab.irbbarcelona.org/oncodrivefml/home. OncodriveFM
and OncodriveCLUST were executed through the web interface at: https://www.
intogen.org/. In order to be considered significant for this tools, a q-value of 0.05
for OncodriveFM and OncodriveCLUST and 0.1 for OncodriveFML were used.
MuSic2 (v0.2) was run using a region of interest (ROI) file for hg19 (obtained
from https://github.com/ding-lab/calc-roi-covg). A gene was considered sig-
nificant if it had an FDR for the Fisher’s combined P value test of <0.05. For
MutSigCV and dNdScv, genes were considered significant at a q-value of <0.1.
The tool 20/20+ was run for 10,000 iterations, using the pre-trained classifier
“2020plus_10k.Rdata”. P value QQ-plots were reviewed and confirmed that the
predictions were not inflated for false positives (mean absolute log2 fold change
(MLFC) was less than 0.3). A gene was significant if the oncogene, tumor
suppressor gene, or driver genes q-values were less than 0.05. A consensus list of
10 significant genes was obtained by considering those genes that were sig-
nificant in at least two different tools (where the Oncosuite methods were
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considered to be one tool). Protein lollipop mutation diagrams were generated
using the tool “lollipops”58.
Structural variant and copy number analysis. Structural variants were deter-
mined using qSV35. Structural variant breakpoints and potential consequence of
the SV, including potential in-frame gene fusions, was determined by annotation
against Ensembl known genes (version 75) using in-house scripts. The presence of
fusion events in COSMIC Cancer census genes and in kinase genes was assessed.
The list of COSMIC Cancer census genes were downloaded 20 December 2017
(https://cancer.sanger.ac.uk/cosmic). All Tier 1 and 2 genes were considered.
Protein kinases were downloaded from Uniprot 20 December 2017 (http://www.
uniprot.org/docs/pkinfam.txt). For genes recurrently affected by rearrangement
breakage sites, COSMIC cancer genes that were rearranged in at least four patients
were included. Genes that were genes identified by SMG analysis in this study, or
are previously identified melanoma driver genes, were also included for SV
analysis.
Copy number was determined using sequencing data and the tool
ascatNGS59. Copy number loss (copy number 1), homozygous deletion (copy
number 0), and amplifications (copy number ≥ 6) were considered in the
analysis. Copy number per gene was determined by annotation against Ensembl
known genes (version 75). Significantly mutated copy number regions were
assessed using GISTIC2.0. A gene was considered significant if it was in a focal
region with a confidence level of 0.95 and a q-value <0.1. A short list of genes
was derived by manual curation and filtering for those genes that are considered
Cosmic Cancer Census genes.
Rearrangement signatures and clustering. We used the same statistical fra-
mework using NMF that was used for mutational signature analysis for the
identification of rearrangement signatures12. SVs were classified into the same
categories as has been described and applied to a breast cancer cohort by Nik-
Zainal and co-workers17. SVs were classified into types of events: deletions,
duplications, inversions, and inter-chromosomal translocations. SVs were fur-
ther characterized by size and whether the breakpoints were clustered or non-
clustered. Size categories (for events that were not translocations) were 1–10 kb,
10–100 kb, 100 kb–1 Mb, 1–10 Mb, more than 10 Mb. Clustered SV breakpoints
were defined using the BEDTools cluster function. Clustered events were defined
using the presence of ≥10 breakpoints in a 1 Mb window, a metric that has
previously been applied by Letouze et al.60. The presence of clustered break-
points on a per-chromosome basis13: chromosomes that had a highly significant
non-random distribution of breakpoints with a stringent threshold of P < 10−5
were considered to be clustered. Chromosomes with high numbers of rearran-
gement events were identified as outliers defined as a breakpoint per megabase
rate exceeding 1.5 times the length of the inter-quartile range from the seventy-
fifth percentile for each sample with a minimum threshold of 35 breakpoints per
chromosome. Chromosomes with at least 10 translocations were defined as
having a high number of translocations.
Unsupervised hierarchical clustering of rearrangement signatures was
performed using the R package “ConsensusClusterPlus”61. The data used for the
clustering were the proportion of rearrangements assigned to the five signatures.
The proportions for each signature were mean centered before clustering and the
following settings were used: pItem= 0.9, pFeature= 0.9, Pearson’s distance
metric, number of repetitions= 1000.
Detection of kataegis. Localized regions of hypermutation, known as kataegis,
were identified using previously established metrics13: inter-mutational distance
was calculated as the number of base pairs between mutations ordered by chro-
mosome and position. Inter-mutational distances were segmented using piecewise
constant fitting and putative regions of kataegis were defined as segments con-
taining six or more consecutive mutations with a mean inter-mutation distance of
≤1000 bp.
Telomere length. TL was determined using sequencing data and the tool qMotif7.
qMotif is freely available at http://sourceforge.net/projects/adamajava and counts
the number of reads containing the telomeric repeat (TTAAGG). Counts are
normalized to the mean genomic coverage of a sample and the relative TL is
expressed as the log2 ratio of read counts in the tumor BAM file to the matched
normal BAM file read counts.
Clinically actionable mutations. The Cancer Genome Interpreter website (www.
cangergenomeinterpreter.org)62 was used to identify clinically actionable
mutations. Mutations that were annotated were: coding SNVs/indels, copy
number alterations that were amplifications (copy number ≥6) or homozygous
deletions (copy number 0), and predicted inter-gene fusions. The output from
the Cancer Genome Interpreter (drug_precriptions.tsv) was filtered as follows:
Alterations= complete, Tested tumor= Contains CANCER or CM. An evidence
level that was preclinical was removed. References to BRAF inhibitor resistance
was removed in samples that did not contain a BRAF mutation.
Statistical analysis. Statistical analyses were performed in R, and p-values < 0.05
were considered statistically significant. Two-sided Fisher’s exact tests were per-
formed where specified. If not specified otherwise, two-sided Mann–Whitney U
statistical tests were carried out. Sample sizes are listed in figures or figure legends.
Boxplots show the median and the 25th and 75th percentiles.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data that support the findings of this study have been desposited in the
European Genome-phenome Archive (EGA). The sequencing data for whole-genome
sequenced samples (from Australia, Sweden, Switzerland, and China) are available under
study accession EGAS00001001552. The raw sequencing data for the UK/USA WES
samples are available under study accession EGAS00001001115. The source data
underlying Fig. 1c and Supplementary Fig. 5 are provided as a Source Data file.
Code availability
Tools used in this publication that were developed in-house are available from the
SourceForge public code repository under the AdamaJava project (http://sourceforge.net/
projects/adamajava/). Updated versions of software are available at https://github.com/
AdamaJava.
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